<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89057">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01920152</url>
  </required_header>
  <id_info>
    <org_study_id>13-0142</org_study_id>
    <nct_id>NCT01920152</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Evaluating Platelet Rich Plasma Versus Hyaluronic-Acid in the Short-term Treatment of Symptomatic OA (Osteoarthritis) of the Hip</brief_title>
  <official_title>A Randomized Clinical Trial Evaluating Platelet Rich Plasma Versus Hyaluronic-Acid in the Short-term Treatment of Symptomatic OA (Osteoarthritis) of the Hip</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the clinical efficacy of intra-articular
      injections of autologous platelet rich plasma (PRP) vs hyaluronic acid (HA) for symptomatic
      early osteoarthritis (OA) of the hip. Secondarily, this study aims to determine the
      feasibility and safety of treating early OA of the hip with HA and PRP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis (OA) is a common, painful condition affect adults and causes mobility
      disability in the United States and Europe.  Unfortunately, there is no agents available
      that halt OA progression.  Analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) have
      suboptimal effectiveness, and there is concern of systemic side effects.

      A large challenge is the development of appropriate and effective therapy in patients with
      OA.  Currently, the most suitable route for administering OA therapy appears to be
      intra-articular injections that allow accumulation of critical doses of the drug within the
      damaged area and also reduce the risk of systemic side effects.

      The primary objective of this study is to compare the clinical efficacy of intra-articular
      injections of Platelet Rich Plasma (PRP) vs. Hyaluronic Acid for symptomatic early OA of the
      hip. Secondarily, the study aims to evaluate the safety and feasibility of both medications
      delivered.

      Patients, which meet inclusion criteria, are confirmed eligible, and agree to enroll in the
      study, would  be randomized and treated with either three intra-articular PRP injections or
      three intra-articular Hyaluronic Acid injections. If the patient has OA in both hips, they
      will be randomized to receive the same injection in both hips.  The Primary investigator
      will be unblinded to the treatment that the subject is randomized to.  The PI will only be
      involved in the initial assessment of the patient and the actual injections.  All of the
      follow up visits, clinical assessments and outcome scores will be performed by the
      sub-investigator, who will also be the examining physician.  The sub-investigator will be
      blinded to the treatment throughout the study.  All of the study subjects will be blinded to
      which treatment that they are assigned to.

      Physical exams will be performed to assess range of motion of the hip joint.  The difference
      in ranges of motion will be statistically compared at different time points between the two
      groups to determine the difference in improvement between the two compared to baseline.

      The primary efficacy outcome will be defined as the percentage of patients having a 50%
      decrease in the summed score for the WOMAC pain subscale from baseline to week 24. We will
      measure this outcome by applying the WOMAC questionnaire compared with baseline therapy. The
      secondary efficacy outcomes will also include IHOT and Non Arthritic Hip Score.

      An anterior posterior hip radiograph will be performed at 12 months and 24 months to assess
      Kellgren-Classification and compared to baseline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index)</measure>
    <time_frame>Baseline-24 months follow up</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary efficacy outcome will be defined as the percentage of patients having a 50% decrease in the summed score for the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscale from baseline to week 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Hip Outcome Tool (IHOT)</measure>
    <time_frame>Baseline-24 months post inoculation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjective score variation in the International Hip Outcome Tool (IHOT) for both groups of treatment from baseline to 24 months post inoculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non Arthritic Hip Score</measure>
    <time_frame>Baseline-24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjective score variation on the Non Arthritic Hip Score for both groups of treatment from baseline to 24 months post inoculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip Range of motion (ROM)</measure>
    <time_frame>Baseline-24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Score variation on hip range of motion for both groups of treatment from baseline to 24 months post inoculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FABER TEST</measure>
    <time_frame>Baseline-24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Score variation for FABER test for both groups of treatment from baseline to 24 months post inoculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior Posterior (AP) Pelvis Radiograph/ Kellgren-Lawrence classification.</measure>
    <time_frame>Baseline-24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Score variation on the Kellgren-Lawrence score for both groups of treatment from baseline to 24 months post inoculation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with Adverse Events</measure>
    <time_frame>Week 2-Week 3 and 6-12-18-24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Type, duration and trend of every adverse event for each patient will be reported</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hip Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients (n=40) randomized to this group of treatment will receive 3 blinded hip intra-articular injections of autologous Platelet-Rich Plasma one week apart each other.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients (n=40) randomized to this group of treatment will receive 3 blinded hip intra-articular injections of hyaluronic acid (SUPARTZ hyaluronate/2.5ml) one week apart each other.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRP</intervention_name>
    <arm_group_label>PRP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic Acid</intervention_name>
    <arm_group_label>Hyaluronic Acid</arm_group_label>
    <other_name>SUPARTZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female age  40-72 inclusive.

          -  Symptomatic early OA of the hip (Kellgren-Lawrence Grade 1-2) documented by x-ray
             taken within the past 6 months.

          -  Women of childbearing potential will be allowed to enroll but must be willing to
             practice one highly effective method of contraception (oral, injectable or implanted
             hormonal methods of contraception, placement of an intrauterine device (IUD) or
             intrauterine system (IUS) condom or occlusive cap with spermicidal
             foam/gel/film/cream/suppository, male sterilization, or true abstinence) throughout
             the study.

        Exclusion Criteria:

          -  Patients with polyarticular disease.

          -  Patients with major conditions such as poorly control diabetes, Cardiac Heart Failure
             (CHF), Chronic Obstructive Pulmonary Disease (COPD) or untreated depression

          -  Patients with blood disorders (Blood disorders (thrombopathy, thrombocytopenia,
             anemia with hemoglobin &lt;9g/dL). Only those patients with a positive history of blood
             disorders will have a cell blood count (CBC) performed a week prior to inclusion in
             the study.

          -  Patients who had intra-articular treatment with steroids within 3 months of
             randomization in this study or received more than 3 previous intra-articular steroid
             injections to the effected hip.

          -  Patients who are pregnant or nursing at the time of consent.

          -  Patients with inflammatory arthritic conditions (e.g. rheumatoid arthritis)

          -  Non-English speaking patients. (Scores used for evaluation have not been validated in
             Spanish)

          -  Patients who had previous hip surgery

          -  Additional disabilities in any of the lower limbs that would interfere with any of
             the clinical assessments.

          -  Chronic use of NSAID (defined as taking NSAID regularly every week for the last 6
             months), steroids or chemotherapy drugs

          -  Treatment with NSAIDs within 15 days prior to randomization in this study

          -  Patients with a BMI over 30. Due to the fact that this study utilize an injection
             technique which may be inaccurate in obese subjects.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omer Mei-Dan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cyndi Long, Research Assistant</last_name>
    <phone>303-441-2175</phone>
    <email>cyndi.long@ucdenver.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cecilia Pascual-Garrido, MD</last_name>
    <email>cecilia.pascual-garrido@ucdenver.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado, Hip Preservation Center, Orthopedic Department</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyndy Long</last_name>
      <email>cyndi.long@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cecilia Pascual-Garrido, MD</last_name>
      <email>cecilia.pascual-garrido@ucdenver.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Omer Mei-Dan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cecilia Pascual-Garrido, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael R Dayton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mei-Dan O, McConkey MO, Petersen B, McCarty E, Moreira B, Young DA. The anterior approach for a non-image-guided intra-articular hip injection. Arthroscopy. 2013 Jun;29(6):1025-33. doi: 10.1016/j.arthro.2013.02.014. Epub 2013 Apr 13.</citation>
    <PMID>23591381</PMID>
  </reference>
  <reference>
    <citation>Mei-Dan O, Carmont M, Laver L, Mann G, Maffulli N, Nyska M. Intra-articular injections of hyaluronic acid in osteoarthritis of the subtalar joint: a pilot study. J Foot Ankle Surg. 2013 Mar-Apr;52(2):172-6. doi: 10.1053/j.jfas.2012.12.008. Epub 2013 Jan 17.</citation>
    <PMID>23333279</PMID>
  </reference>
  <reference>
    <citation>Mei-Dan O, Carmont MR, Laver L, Mann G, Maffulli N, Nyska M. Platelet-rich plasma or hyaluronate in the management of osteochondral lesions of the talus. Am J Sports Med. 2012 Mar;40(3):534-41. doi: 10.1177/0363546511431238. Epub 2012 Jan 17.</citation>
    <PMID>22253252</PMID>
  </reference>
  <reference>
    <citation>Mei-Dan O, Laver L, Nyska M, Mann G. [Platelet rich plasma--a new biotechnology for treatment of sports injuries]. Harefuah. 2011 May;150(5):453-7, 490. Review. Hebrew.</citation>
    <PMID>21678642</PMID>
  </reference>
  <reference>
    <citation>Mei-Dan O, Lippi G, SÃ¡nchez M, Andia I, Maffulli N. Autologous platelet-rich plasma: a revolution in soft tissue sports injury management? Phys Sportsmed. 2010 Dec;38(4):127-35. doi: 10.3810/psm.2010.12.1835. Review.</citation>
    <PMID>21150152</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>December 11, 2013</lastchanged_date>
  <firstreceived_date>August 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hip, Chondropenia, Osteoarthritis.</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
